SCHEDULE: Cowen Financial Products Divests UroGen Pharma Stake
Schedule 13G Amendment
Cowen Financial Products LLC has reported a complete divestment of its beneficial ownership in UroGen Pharma Ltd. ordinary shares.
Summary
- Cowen Financial Products LLC, a Delaware entity, has filed an Amendment No. 2 to Schedule 13G regarding its beneficial ownership in UroGen Pharma Ltd.
- The filing indicates that Cowen Financial Products LLC no longer holds any beneficial ownership in UroGen Pharma Ltd.'s ordinary shares.
- As of the event date, Cowen Financial Products LLC's aggregate beneficial ownership is 0 shares, representing 0% of the class.
- The beneficial ownership of the subject securities was transferred to The Toronto Dominion Bank, an affiliated entity of Cowen Financial Products LLC, between the date of the event and the filing date.
Sentiment
Score: 5
Explanation: The filing is a neutral, factual disclosure of a change in beneficial ownership by an institutional investor, with no direct positive or negative implications for the issuer's operational or financial performance.
Future Outlook
No forward-looking statements or guidance were provided in this filing.
Industry Context
This filing reflects a change in institutional ownership for UroGen Pharma Ltd., with Cowen Financial Products LLC transferring its holdings to an affiliated entity. Such transfers are common for large financial institutions managing their portfolios and do not inherently indicate a change in the underlying company's fundamentals or broader industry trends.
Related Party Transactions
- Beneficial ownership was transferred to The Toronto Dominion Bank, an affiliated entity of Cowen Financial Products LLC.
Stakeholder Impact
- Shareholders: Minimal direct impact, as it represents a change in the reporting entity for a block of shares, not necessarily a sale into the open market. The overall institutional ownership structure may shift slightly.
Key Dates
| Date | Description |
|---|---|
| 09/30/2025 | Date of event which required the filing of this statement (transfer of beneficial ownership). |
| 11/13/2025 | Date the Schedule 13G Amendment No. 2 was signed by Cowen Financial Products LLC. |
Keywords
UroGen Pharma, Cowen Financial Products, Schedule 13G, Beneficial Ownership, Divestment, Ordinary Shares, SEC Filing, M96088105
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.